malignant fungating wounds. no approved treatment. $HIND filed today for orphan drug designation for VT-1953 to go after exactly that gap. if granted: 7-year market exclusivity, fda fee waivers, tax credits on clinical spend.
Q1 alongside: $8.8m cash, $963k net loss. lean burn for a clinical company. the january raise of $5.29m came in at a 59.2% premium to market. somebody paid up before these catalysts landed.
may 12 brought the impetis biosciences licensing deal. now the ODD application. conference call june 3 for anyone tracking the setup.
https://t.co/QIvWabWUY7
@eEInmobiliaria Despues se quejan de que Vox suba y hay que inventar una estrategia para que la derecha no sume y ellos puedan seguir chupando de la teta. Ellos mismos estan destrozando la izquierda para poder seguir con su modus vivendi. Poco nos passa…. o les passa #asino